| Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044) |
|---|
| 02/15/2005 | CA2293728C Nanocapsules based on water-dispersible anionic polymers, the process of preparing them, and cosmetic or dermatological compounds containing them |
| 02/15/2005 | CA2275626C Homogeneous preformulations containing high concentrations of steroids, for producing low-dose solid and semi-solid pharmaceutical preparations |
| 02/15/2005 | CA2156821C Lidocaine aerosol anaesthetic |
| 02/15/2005 | CA2156408C Aerosol formulation containing a polyester dispersing aid |
| 02/15/2005 | CA2141056C Treatment of dentoalveolar infections with taurolidine and/or taurultam |
| 02/15/2005 | CA2123232C Pharmaceutical compositions containing ebastin or analogs thereof |
| 02/14/2005 | CA2437250A1 Microencapsulation of living cells in covalently crosslinked alginate-poly-l-lysine-alginate membranes |
| 02/13/2005 | CA2470866A1 Uses of dorzolamide to improve night vision |
| 02/12/2005 | CA2477357A1 Sprayable skin protectant compositions |
| 02/12/2005 | CA2437266A1 Taste-masked resinate and preparation thereof |
| 02/11/2005 | CA2437639A1 Manufacture of long term drug delivery devices with polyurethane based polymers |
| 02/10/2005 | WO2005012489A2 Targeting endothelium for tissue-specific delivery of agents |
| 02/10/2005 | WO2005012488A2 Compositions for encapsulation and controlled release |
| 02/10/2005 | WO2005012356A2 Gelatin capsules |
| 02/10/2005 | WO2005012353A1 Crystalline tumor necrosis factor receptor 2 polypeptides |
| 02/10/2005 | WO2005012233A1 Meldonium salts, method of their preparation and pharmaceutical composition on their basis |
| 02/10/2005 | WO2005012176A1 Highly oil absorbing amorphous silica particles |
| 02/10/2005 | WO2005012175A1 Amorphous silica particles having high absorbing capabilities and high structural characteristics |
| 02/10/2005 | WO2005011813A2 Treatment of ocular disease |
| 02/10/2005 | WO2005011797A1 Method and device for improving the permeability of the human skin |
| 02/10/2005 | WO2005011767A1 Implantable or insertable medical devices containing silicone copolymer for controlled delivery of therapeutic agents |
| 02/10/2005 | WO2005011752A1 Method of sterilization by irradiation of polymeric materials suitable for therapeutical purposes |
| 02/10/2005 | WO2005011741A2 Delivery of a drug via subconjuctival or periocular delivery of a prodrug in a polymeric microparticle |
| 02/10/2005 | WO2005011740A1 Use of recombinant or synthetic gelatin-like proteins as stabiliser in lyophilized pharmaceutical compositions |
| 02/10/2005 | WO2005011737A2 Pharmaceutical combinations and formulations with improved stability |
| 02/10/2005 | WO2005011707A1 A doxycycline metal complex in a solid dosage form |
| 02/10/2005 | WO2005011704A1 Product containing prostaglandin |
| 02/10/2005 | WO2005011702A1 Process for preparing particles containing an antiviral |
| 02/10/2005 | WO2005011698A1 Combination comprising a liposome-encapsulated vinca alkaloid and a topoisomerase ii inhibitor and the use thereof for treating neoplasia |
| 02/10/2005 | WO2005011691A1 Improved binding of pantoprazole to the proton pump |
| 02/10/2005 | WO2005011688A1 Cci-779 lyophilized formulations |
| 02/10/2005 | WO2005011687A1 Transdermaltherapeutic system containing a pramipexol active agent |
| 02/10/2005 | WO2005011683A1 Transdermal absorption preparation |
| 02/10/2005 | WO2005011682A1 Sustained release tablet for oral use |
| 02/10/2005 | WO2005011672A1 Processed fat composition for preventing/ameliorating lifestyle-related diseases |
| 02/10/2005 | WO2005011669A1 Medicinal composition for percutaneous administration |
| 02/10/2005 | WO2005011667A1 Methods of therapeutic treatment using amounts of retinoid components |
| 02/10/2005 | WO2005011666A1 Stable sustained release oral dosage form of gabapentin |
| 02/10/2005 | WO2005011662A1 Adhesive patch |
| 02/10/2005 | WO2005011652A2 Use of a vitamin d receptor activator or a vitamin d analog to treat kidney disease |
| 02/10/2005 | WO2005011651A2 Use of a vitamin d receptor activator or a vitamin d analog to treat cardiovascular disease |
| 02/10/2005 | WO2005011650A1 Tranexamic acid formulations with reduced adverse effects |
| 02/10/2005 | WO2005011644A1 Transdermal warfarin-containing delivery system |
| 02/10/2005 | WO2005011643A1 Biliquid foams, stable dispersions thereof and a corresponding process of manufacturing |
| 02/10/2005 | WO2005011642A1 Single unit pharmaceutical composition comprising a mixture of a fibrate and an homocysteine reducing agent |
| 02/10/2005 | WO2005011641A2 Improved stearate composition and method of production thereof |
| 02/10/2005 | WO2005011640A2 Pharmaceutical desmopressin composition as solid dosage form and method for manufacturing thereof |
| 02/10/2005 | WO2005011639A2 Effervescent pharmaceutical compositions containing vitamin d, calcium and phospate and their therapeutic use |
| 02/10/2005 | WO2005011638A2 Methods for the stabilization of atorvastatin |
| 02/10/2005 | WO2005011637A1 At-use dispersed preparation |
| 02/10/2005 | WO2005011636A2 Spray drying processes for forming solid amorphous dispersions of drugs and polymers |
| 02/10/2005 | WO2005011635A2 Pharmaceutical compositions of adsorbates of amorphous drugs and lipophilic microphase-forming materials |
| 02/10/2005 | WO2005011634A1 Dosage forms providing controlled release of cholesteryl ester transfer protein inhibitors and immediate release of hmg-coa reductase inhibitors |
| 02/10/2005 | WO2005011633A1 Remedy or diagnostic for inflammatory disease containing target-directing liposome |
| 02/10/2005 | WO2005011632A1 Target-directed and enteric absorption-controlled liposome having sugar chain and cancer remedy and diagnostic containing the same |
| 02/10/2005 | WO2005011631A1 Dialysis solutions with reduced levels of glucose degradation products |
| 02/10/2005 | WO2005011630A2 Permeation-resistant osmotic engine and dosage form for controlled release of a liquid active agent formulation |
| 02/10/2005 | WO2005011629A1 Bioactive compositions comprising triazines |
| 02/10/2005 | WO2005011628A2 Oral delivery system comprising a biliquid foam |
| 02/10/2005 | WO2005011620A2 Methods and apparatus for creating particle derivatives of hdl with reduced lipid content |
| 02/10/2005 | WO2005011618A2 Methods for the treatment of male and female sexual dysfunction |
| 02/10/2005 | WO2005011617A2 Transmucosal dosage forms for brain-targeted steroid chemical delivery systems |
| 02/10/2005 | WO2005011616A2 Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a cromone for treatment of asthma or chronic obstructive pulmonary disease |
| 02/10/2005 | WO2005011614A2 Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anti-ige antibody for treatment of asthma or chronic obstructive pulmonary disease |
| 02/10/2005 | WO2005011602A2 Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a pde-4 inhibitor for treatment of asthma or chronic obstructive pulmonary disease |
| 02/10/2005 | WO2005011600A2 Sterile preparations of phospholipids and anti-inflammatory pharmaceuticals and methods for making and using same |
| 02/10/2005 | WO2005011595A2 Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a leukotriene receptor antagonist for treatment of asthma or chronic obstructive pulmonary disease |
| 02/10/2005 | WO2005011586A2 Treatment and preventi0n of cardiovascular events |
| 02/10/2005 | WO2005011580A2 Compositions and methods for herpes simplex prophylaxis and treatment |
| 02/10/2005 | WO2005011579A2 Treatment of dependence withdrawal |
| 02/10/2005 | WO2005011575A2 Stabilization and ionic triggering of nitric oxide release |
| 02/10/2005 | WO2005011570A2 Calcium carbonate granulation |
| 02/10/2005 | WO2005011567A2 Foam carrier containing amphiphilic copolymeric gelling agent |
| 02/10/2005 | WO2005011402A1 Masticatable capsule and process for producing the same |
| 02/10/2005 | WO2004112748A3 Rate controlled release of a pharmaceutical agent in a biodegradable device |
| 02/10/2005 | WO2004110480A3 Polyanionic polymer adjuvants for haemophilus influenza b saccharide vaccines |
| 02/10/2005 | WO2004108911A3 Method for production of enzyme granules and enzyme granules produced thus |
| 02/10/2005 | WO2004105485A3 Inducible release vehicles |
| 02/10/2005 | WO2004098564A3 Biodegradable nanoparticles comprising an aminoglycoside and a polymer like a polysaccharide |
| 02/10/2005 | WO2004089335A3 Non-aqueous single phase vehicles and formulations utilizing such vehicles |
| 02/10/2005 | WO2004073652A3 Powder formulations of recombinant staphylococcal enterotoxin b (rseb) made by atmospheric spray-freeze drying for improved vaccination |
| 02/10/2005 | WO2004035032A3 Pharmaceutical formulations of camptothecine derivatives |
| 02/10/2005 | WO2004032826A8 Process for preparing tannate tablet capsule or other solid dosage forms |
| 02/10/2005 | US20050033417 Coating for controlled release of a therapeutic agent |
| 02/10/2005 | US20050033414 Drug-eluting stent with multi-layer coatings |
| 02/10/2005 | US20050033376 Systems and methods for trestment of obesity and eating disorders by electrical brain stimulation and/ or drug infusion |
| 02/10/2005 | US20050033373 Method, system and device for treating disorders of the pelvic floor by the delivering of drugs to the sacral nerves |
| 02/10/2005 | US20050033372 Method, system and device for treating disorders of the pelvic floor by electrical stimulation of the left and the right sacral nerves |
| 02/10/2005 | US20050033261 Drug/drug delivery systems for the prevention and treatment of vascular disease |
| 02/10/2005 | US20050033132 Analyte measuring device |
| 02/10/2005 | US20050033065 Transdermal therapeutic system which contains a D2 agonist and which is provided for treating parkinsonism, and a method for the production thereof |
| 02/10/2005 | US20050032912 Inhalation formulation of a suspension of the anaesthetic agent such as enflurane, desflurane, propofol in aqueous medium; without the problem of condensation of the anaesthetic within the administration apparatus and/or delivery tubes to the patient |
| 02/10/2005 | US20050032905 Water soluble liquid solution of (R)-N,N-diisopropyl-3-(2-hydroxy-5-methylphenyl)-3-phenylpropanamine, a sweetening agent and an antimicrobial agent; antimuscarinic activity |
| 02/10/2005 | US20050032900 For topical administration, without the presence of conventional oil in water (O/W) emulsifying agent; percutaneous delivery of ibuprofen is improved by using a skin penetration enhancer, such as 2-n-nonyl-1,3-dioxolane or decanal, dimethyl acetal, as the oily phase of the emulsion |
| 02/10/2005 | US20050032894 Method for manufacturing calcium gluconolcatate compositions, processes and uses |
| 02/10/2005 | US20050032880 Dissolving atorvastatin in alcoholic solvent comprising methanol, ethanol, 1-propanol, or isopropanol; high speed evaporation by spray drying |
| 02/10/2005 | US20050032878 Peroxisome proliferator activated compound of fenofibrate, ciprofibrate, clofibrate, gemifibrozil and/or bezafibrate; and pravastatin, simvastatin, lovastatin, fluvastatin, atorvastatin, cerivastatin, pravastatin and/or mixtures; and polyglycolized glyceride; dissolving, bioavailability |
| 02/10/2005 | US20050032876 Pharmaceutical compositions comprising sumatriptan and metoclopramide, and methods of use thereof |
| 02/10/2005 | US20050032867 Pharmaceutical composition comprising a 5ht1 receptor agonist |
| 02/10/2005 | US20050032866 Administering N-[(1-butyl-4-piperidinyl)methyl]-3,4-dihydro-2H-[1,3]oxazino[3,2-a]indole-10-carboxamide or salt as antiarrhythmia agent |